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Giant congenital nevi are pigmented childhood lesions that frequently lead to 
melanoma, the most aggressive skin cancer. The mechanisms underlying this 
malignancy are largely unknown, and effective therapies are missing. Here we 
describe a mouse model for giant congenital nevus and show that nevi and 
melanoma prominently express Sox10, a transcription factor crucial for the 
formation of melanocytes from the neural crest. Strikingly, Sox10 
haploinsufficiency counteracts NrasQ61K–driven congenital nevus and melanoma 
formation without affecting physiological functions of neural crest derivatives in 
the skin. Moreover, Sox10 is also crucial for maintenance of neoplastic cells in vivo. 
In human patients, virtually all congenital nevi and melanomas are SOX10 
positive. Furthermore, SOX10 silencing in human melanoma cells suppresses 
neural crest stem cell properties, counteracts proliferation and cell survival, and 
completely abolishes in vivo tumor formation. Thus, SOX10 represents a 
promising target for treatment of congenital nevi and melanoma in human 
patients. 
 
Human giant congenital nevi are associated with a high risk of melanoma. Mutations in 
NRAS are frequently found in human giant congenital nevi and melanomas, while BRAF 
mutations are usually not detected in giant congenital nevi1-3. Moreover, mutations in 
the INK4a locus that lead to inactivation of tumor suppressor genes are most common in 
human melanoma. In a melanoma mouse model, overexpression of the NrasQ61K 
oncogene under the control of tyrosinase promoter, in combination with loss of INK4a, 
results in melanoma formation with a high penetrance (>90%) at around 6 months of 
age4. In contrast, INK4a-/- mice barely develop melanoma5. Tyr::NrasQ61K expression is, 
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therefore, the key event underlying melanoma formation in the Tyr::NrasQ61K INKa-/- 
mouse model. Intriguingly, morphological appearance and histological analysis of the 
skin of Tyr::NrasQ61K mice showed some challenging similarities to human giant 
congenital nevus such as hyperpigmentation of the nevus nests close to the epidermis 
and location of nevus cells around and within hair follicles and other adnexal structures, 
such as sebaceous glands (Fig. 1). As in human patients, skin hyperpigmentation was 
apparent already at first postnatal week in Tyr::NrasQ61K and Tyr::NrasQ61K INK4a-/- 
mice and was restricted to the dermis with virtually no epidermal involvement (Fig. 1d-
f). Thus, Tyr::NrasQ61K INK4a-/- mice represent a model for melanoma arising from giant 
congenital nevi. 
 
The transcription factor Sox10 is a key regulator of pigment cell formation during 
embryonic development and is expressed throughout all stages of melanocyte 
differentiation6-9. To investigate whether Sox10 is also expressed in pathological lesions 
associated with the melanocytic lineage, we first performed immunohistochemical 
analysis of human giant congenital nevi and revealed that SOX10 was highly expressed 
in all of the tested samples (n=17) (Fig. 2a,b, Supplementary Fig. S1a,b and 
Supplementary Table S1). Furthermore, extending studies by others10-14, we analyzed 
expression of SOX10 in a large set of human primary melanomas and melanoma 
metastases15. We found that the vast majority of all melanoma samples displayed 
nuclear SOX10 staining (Fig. 2c,d). Of note, 100% of all primary melanomas were 
marked by SOX10 expression, with more than 90% of all cells being SOX10-positive in 
85% of all samples tested (n=48). Of the metastatic samples, only 13% of the samples 
exhibited either very restricted or no nuclear SOX10 staining (n=130) (Fig. 2d). In 
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contrast, MITF, a transcription factor previously implicated in melanoma biology16, was 
not expressed in all primary melanoma samples and, in particular, absent in 11% of 
tumor biopsies exhibiting dominant SOX10 expression (Supplementary Fig. S1c,d). 
Therefore, SOX10 might serve as a more sensitive marker for human giant congenital 
nevus and melanoma than other currently used markers including MITF. 
 
In analogy to the human situation, dermal lesions reminiscent of giant congenital nevi 
exhibited broad Sox10 expression in Tyr::NrasQ61K and Tyr::NrasQ61K INK4a-/- mice 
from early postnatal stages onwards (Fig. 2e). Moreover, Sox10 was prominently 
expressed in tumors generated in Tyr::NrasQ61K INK4a-/- mice at 6 months of age (Fig. 
2f). To address whether expression of Sox10 might be regulated by oncogenic NrasQ61K, 
we purified melanocytic cells from the skin of one month old wild type and 
Tyr::NrasQ61K mice by fluorescent activated cell sorting (FACS), using the lineage 
markers MelanA and c-Kit for cell surface labeling (Fig. 2g). Quantitative real time 
PCR analysis of the resulting cell fractions demonstrated that Sox10 expression was 
significantly increased in melanoblasts from Tyr::NrasQ61K mice as compared to control 
melanoblasts, revealing NrasQ61K-mediated Sox10 activation (Fig. 2h). The combined 
findings strongly suggest a central role of SOX10 in both giant congenital nevus and 
melanoma formation in human and mice.  
 
During development, melanocytes arise from the neural crest, a transient embryonic 
structure containing multipotent neural crest stem cells (NCSCs). Absence of Sox10 
affects NCSC survival and leads, therefore, to a loss of neural crest derivatives, 
including melanocytes6, 7, 17. In mice heterozygous for Sox10 null mutations, however, 
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most neural crest derivatives are properly generated during development, although 
neural crest stem and progenitor cell maintenance, proliferation, and fate decisions are 
impaired6, 9, 18-22. In particular, both in human and mice, Sox10 haploinsufficiency is 
compatible with normal melanocyte specification and differentiation, but interferes with 
the generation of proper pigment cell numbers during development, leading to 
characteristic pigmentation defects at birth. In the adult, however, physiological 
pigmentation is not affected by monoallelic Sox10 expression. 
 
Based on this knowledge, we reasoned that Sox10 haploinsufficiency might possibly 
interfere with aberrant melanocytic cell production during the generation of giant nevi 
and melanoma without disturbing normal cell function. To test this hypothesis, we made 
use of Sox10LacZ/+ mutant mice, in which the complete open reading frame of Sox10 has 
been replaced by LacZ sequences6 (Fig. 3a). Strikingly, in Tyr::NrasQ61K and 
Tyr::NrasQ61K INK4a-/- mice, Sox10 haploinsufficiency counteracted NrasQ61K–
dependent hyperpigmentation, as evident by the morphological appearance of snout, 
paws, and other skin areas (Fig. 3a,b and Supplementary Fig. S2a). The loss of 
hyperpigmentation in Tyr::NrasQ61K INK4a-/- Sox10LacZ/+ mice became particularly 
apparent upon shaving of the back skin of the animals (Fig. 3b). These data were 
confirmed by histological analysis of skin sections. While virtually all hair follicles 
(HFs) were associated with ectopic pigmentation in Tyr::NrasQ61K and Tyr::NrasQ61K 
INK4a-/- mice (95±5 and 94±6%, respectively), Sox10 heterozygosity efficiently 
reverted this phenotype to an almost normal pigmentation pattern (HFs with ectopic 
pigmentation: 8±2% and 9±2%, respectively) (Fig. 3c,d). Likewise, the number of 
dermal cells positive for the melanocytic markers S100 or Dct23-25 was massively 
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reduced due to Sox10 haploinsufficiency (Fig. 3c and Supplementary Fig. S2c,d). 
Tyr::NrasQ61K Sox10LacZ/+ and Tyr::NrasQ61K INK4a-/- Sox10LacZ/+ mice displayed 
pigment cells in HF bulbs and no precocious hair graying, however, revealing normal 
generation of melanocytes in these animals (Supplementary Fig. S2a,b).  
 
To assess whether Sox10 haploinsufficiency not only influences congenital nevus, but 
also subsequent melanoma formation, Tyr::NrasQ61K INK4a-/- Sox10LacZ/+ mutant mice 
were monitored for several months, together with Tyr::NrasQ61K INK4a-/- control 
animals. Whereas 100% of the control mice developed macroscopically visible 
melanomas4, skin examination of Tyr::NrasQ61K INK4a-/- Sox10LacZ/+ mice at 6 months 
of age revealed no morphological signs of primary melanoma formation (n=18) (Fig. 
3e,f and Supplementary Fig. S2b). These findings demonstrate efficient inhibition of 
melanoma formation by Sox10 haploinsufficiency in mice.  
 
During embryonic development, Sox10 regulates the balance between NCSC 
maintenance and multilineage differentiation17, 26. In particular, Sox10 
haploinsufficiency counteracts maintenance and expansion of proliferative progenitor 
cells in different neural crest target structures27, 28. Therefore, to study the mechanisms 
underlying Sox10-dependent congenital nevus and melanoma formation, we addressed 
whether Sox10 haploinsufficiency affects cell proliferation by quantifying the number 
of Dct-positive cells expressing the proliferation marker Ki67 in wild type, 
Tyr::NrasQ61K, and Tyr::NrasQ61K Sox10LacZ/+ mice (Fig. 3g-j). To this end, cell 
proliferation was assessed in melanocytic cells localized to HFs because this cellular 
compartment was present in all three genotypes. In the bulb area with differentiated 
 7
melanocytes (Fig. 3i,j) and in particular in the bulge area containing undifferentiated 
cells of the melanocyte lineage (Fig. 3g,h), expression of NrasQ61K led to a highly 
significant increase in the number of proliferative Dct-positive cells. In Tyr::NrasQ61K 
Sox10LacZ/+ mice, however, proliferation was reduced to almost control levels (Fig. 3g-
j). These experiments demonstrate that one of the main antagonistic effects of Sox10 
haploinsufficiency on tumorigenesis is to counteract NrasQ61K-induced 
hyperproliferation.  
 
To assess the importance of Sox10 functions for the maintenance of already established 
lesions, we used Tyr-CreERT2 mice to conditionally induce Sox10 heterozygosity in 
two months old Tyr::NrasQ61K mice carrying a Sox10fl allele29 (Fig. 4a,b). To achieve 
inducible Cre-dependent recombination and thus loss of Sox10 expression from the 
Sox10fl allele, mice were injected with tamoxifen at two months of age, followed by 
their analysis at 12 month (Fig. 4a). Intriguingly, hyperpigmentation was efficiently 
reverted in the back skin, snout and paws of these mice (Fig.4b). Moreover, histological 
analysis of skin sections showed that induced Sox10 haploinsufficiency resulted in an 
almost complete disappearance of ectopic dermal cells positive for pigment or Dct (Fig. 
4c). Indeed, while 96 ± 1% of all HFs were associated with ectopic Dct-positive cells in 
Tyr::NrasQ61K Sox10fl/+ mice, this number was reduced to 10 ± 3% in Tyr::NrasQ61K 
Sox10fl/+Tyr-CreERT2 mice upon tamoxifen-induced Cre-mediated recombination (Fig. 
4d). Thus, Sox10 is required not only for the formation but also for the maintenance of 
pre-melanoma lesions. 
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To address the relevance of these findings for human melanoma, we assessed whether in 
analogy to the mouse model, decreasing levels of SOX10 in human melanoma cell lines 
would interfere with melanoma maintenance. To this end, we performed RNA 
interference (RNAi)-mediated silencing of SOX10 in human melanoma cell lines30. In 
two distinct cell lines, SOX10 shRNA resulted in efficient downregulation of SOX10 
expression, as revealed both by Western blot analysis and immunocytochemistry 
(Supplementary Fig. S3). The capacity to form clones consisting of two or more cells 
was significantly reduced upon SOX10 knockdown (Fig. 4e; clonogenicity of cells 
expressing control shRNA, 27 ± 2%; SOX10 shRNA, 4 ± 1%). To investigate in vivo 
tumor formation, immunocompromized mice were injected subcutaneously with 
melanoma cells expressing either SOX10 or control shRNA. After 8 weeks, control cells 
consistently produced large, macroscopically evident tumors in vivo (11 out of 14 
injections; Fig. 4f). In striking contrast, none of the subcutaneous injections with SOX10 
shRNA-expressing melanoma cells (0/16) led to tumor formation, even when the mice 
were kept for an additional 6 weeks. These data demonstrate that silencing of SOX10 
very effectively blocks tumorigenesis by human melanoma cells in vivo.  
 
To address the mechanisms by which SOX10 controls human melanoma formation, we 
performed a comparative genome-wide transcriptome analysis of control vs. SOX10 
shRNA-expressing melanoma cells 48 and 96 hours after RNAi-mediated silencing. 
Cluster analysis of transcriptionally regulated genes indicated that reducing SOX10 
levels promotes apoptosis, cell cycle exit, and mesectodermal differentiation (Fig. 4g 
and Supplementary Fig. 4a). These data were confirmed by measuring changes in 
expression levels of 233 genes 48 and 96 hours after SOX10 shRNA treatment, using 
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quantitative real time PCR (Fig. 4h,i, Supplementary Fig. 4b-f). Several genes encoding 
apoptosis-control factors were dysregulated upon silencing of SOX10 (Fig. 4h). For 
instance, the anti-apoptotic factor BCL2 was significantly downregulated, while pro-
apoptotic factors such as CASP1 and multiple TNF pathway components were highly 
upregulated in SOX10 knockdown cells. Moreover, RNAi-mediated silencing of SOX10 
led to highly reduced expression of almost all genes tested that encode cyclins and 
cyclin dependent kinases (CDKs), which trigger progression through the cell cycle (Fig. 
4i and Supplementary Fig. 4d). Thus, in human melanoma cells, SOX10 controls 
multiple genes associated with cell survival and proliferation.  
 
To functionally demonstrate the cell death-promoting effect of SOX10 silencing, we 
quantified the number of Annexin V-positive cells using FACS analysis (Fig. 5a-c and 
Supplementary Fig. 5a-d). This method revealed that in both human melanoma cell lines 
tested, the number of dying cells was significantly increased 48 and 96 hours after 
SOX10 shRNA treatment of the cells (Fig. 5c). Likewise, expression of SOX10 shRNA 
led to a more than 9 fold increase in the percentage of apoptotic cells positive for 
activated Caspase 3 (Supplementary Fig. 5c,d). Together, these experiments revealed an 
important role of SOX10 in supporting the survival of melanoma cells. To address the 
function of SOX10 in cell cycle control, we analyzed the cell cycle profile in control vs. 
SOX10 shRNA-expressing human melanoma cells. These experiments demonstrated 
decreased cell cycle progression upon SOX10 knock down (Fig. 5d-f and 
Supplementary Fig. 5e-j). Therefore, SOX10 is required for the maintenance of 
proliferative melanoma cells. Finally, as shown by immunocytological assays, loss of 
SOX10 promoted the formation of large, myofibroblast-like cells and expression of 
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SOX9, which in neural crest development marks mesectodermal progenitor cells28 (Fig. 
5g,j). In addition, the vast majority of SOX10 shRNA-expressing melanoma cells lost 
expression of the melanoma marker HMB45/MART-1 (Fig. 5h,k). These findings are 
highly reminiscent of the effects seen upon Sox10 loss of function in normal NCSCs, 
which include aberrant fate decisions, altered proliferation and survival, and increased 
differentiation into the mesectodermal lineages17, 28. Thus, SOX10 shRNA expression in 
human melanoma cells appears to interfere with NCSC properties. In support of this, 
SOX10 inactivation led to a drastic reduction in the number of cells expressing the 
NCSC marker CD271 (p75NTR) (Fig. 5i,l). Intriguingly, this marker has been associated 
before with cells implicated in melanoma initiation and propagation10, 31, which offers a 
plausible explanation for the anti-tumorigenic effect of SOX10 silencing. 
 
In this study, we demonstrate intriguing similarities between the Tyr::NrasQ61K mouse 
model and human melanomas arising in giant congenital nevi. These nevi often carry 
Nras mutations and are associated with a dermal origin of the malignant melanocytic 
tumor cell population. Although melanoma formation in this model implicates the loss 
of tumor suppressor genes encoded by INK4a, the key event required for nevus 
formation and tumorigenesis is activation of NrasQ61K associated with expression of the 
transcription factor Sox10. Intriguingly, Sox10 haploinsufficiency fully prevents 
NrasQ61K–driven formation of premalignant lesions and tumors. In human melanoma 
cells, suppression of SOX10 counteracts melanoma formation by interfering with NCSC 
features and decreasing the number of CD271-positive tumor-initiating cells. Based on 
our data, SOX10 levels might represent a molecular target to suppress giant congenital 
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nevi and their malignant transformation and to interfere with expansion of established 
melanomas. 
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Figure 1. Histological analysis of skin of Tyr::NrasQ61K mice reveals lesions similar 
to human giant congenital nevus. a, Clinical features of congenital giant hairy nevus 
from human patient (girl, 6 months of age). b, Clinical features of giant congenital 
nevus (bathing trunk nevus) from human patient (girl, 12 years of age). c, Histological 
appearance of human giant congenital nevus. Note the lack of epidermal involvement. 
Scale bar, 50 μm. d, Picture of representative WT and Tyr:: NrasQ61K mice at postnatal 
day 9. e, Pictures of snouts and paws of WT and Tyr:: NrasQ61K mice. Note 
hyperpigmentation of the skin of Tyr:: NrasQ61K mice as compared to WT mice. Scale 
bars, 2 mm. f, Histological appearance of skin from Tyr:: NrasQ61K mice. Scale bar, 50 
μm. H&E, haematoxilin and eosin, P9, postnatal day 9, SG, sebaceous gland, WT, wild 
type.  
 
Figure 2. SOX10 expression is a reliable marker for giant congenital nevi, primary 
melanoma and melanoma metastases in Tyr::NrasQ61KINK4a-/- mice and in human 
patients. a, Immunostaining for SOX10 (nuclear, red) of skin from a human patient 
(girl, 6 months of age). Left panel, normal skin with SOX10-positive melanocytes; right 
panel, giant congenital nevus from the same patient. b, 17 samples of giant congenital 
nevi from different human patients were divided into three subgroups based on the size 
of the congenital nevi: group I (1.5 to 10 cm), group II (11 to 20 cm) and group III (21 
to 40 cm). Nuclear SOX10 staining (red) was detected in all 17 samples analyzed 
independently of their size. c, d, Immunostaining for SOX10 in human melanomas. One 
primary and two different metastatic TMA (tissue microarray) were scored based on the 
percentage of SOX10-positive nuclear staining in melanoma cells (arrows). Samples 
were divided into four groups with expression in less than 10% of tumor cells (group I), 
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from 10 to 50 % (group II), from 50 to 90% (group III), and in more than 90% (group 
IV) of all tumor cells. Insets show high magnification views; n=178 melanomas. e, f, 
Sox10 expression (red) was also detected in giant congenital nevi (mouse at postnatal 
day 9) and melanoma (6 months old mouse) in Tyr::NrasQ61KINK4a-/- mouse model. g, 
h, Sox10 is upregulated upon expression of NrasQ61K oncogene. g, Fluorescence 
histogram of gated cells of the melanocytic lineage from the trunk skin of one month 
old WT and Tyr::NrasQ61K mice stained with a combination of MelanA  and c-Kit 
antibodies. h, Cells from the MelanA/c-Kit double positive fraction were used for RNA 
isolation and subsequent quantitative real-time PCR analysis of Sox10 expression. n = 3 
independent experiments. Data are presented as the mean fold change ± s.d. and are 
normalized to the control. BF, bright field, HF, hair follicle; SG, sebaceous gland. Scale 
bars, 50 μm. 
 
Figure 3. Sox10 haploinsufficiency counteracts Tyr::NrasQ61K–mediated 
hyperpigmentation and melanoma formation by counteracting NrasQ61K–
dependent proliferation. a, Experimental strategy used to analyze the effect of Sox10 
haploinsufficiency in Tyr::NrasQ61K and Tyr::NrasQ61K INK4a-/- mice. b, Pictures of two 
representative mice at 5 months of age show no skin hyperpigmentation in 
Tyr::NrasQ61KINK4a-/-Sox10LacZ/+ mice. Scale bars, 5 mm. c, H&E staining (left panels) 
and immunostaining for S100 (right panels) of skin sections from Tyr::NrasQ61K and 
Tyr::NrasQ61KSox10LacZ/+ mice. Scale bars, 20 μm. d, Quantification of percentage of 
hair follicles (HFs) displaying ectopic pigmentation. Data are presented as mean ± s.d. 
(n=300 HFs quantified from three different mice for each genotype). e, Photograph 
showing pigmented melanoma (black arrows) in 6 month old Tyr::NrasQ61K INK4a-/- 
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mouse (left) and melanoma-free Tyr::NrasQ61K INK4a-/-Sox10LacZ/+ littermate mouse 
(right). To demonstrate presence of melanoma, mice with light coat color were used for 
this picture. Note that there is no hair greying in mice of both genotypes 
(Supplementary Fig. S2). f, Graph showing percentage of melanoma-free Tyr::NrasQ61K 
INK4a-/- (n=23 mice) and Tyr::NrasQ61K INK4a-/- Sox10LacZ/+ (n=18 mice)  mice at 7 
months of age. g, i, Immunostaining for Dct (green) and Ki67 (red) showing 
proliferation of cells of the melanocytic lineage in the upper part of the HF (g) and in 
the HF bulb (i) in WT, Tyr::NrasQ61K and Tyr::NrasQ61KSox10LacZ/+ mice (insets show 
high magnification views). Scale bars, 20 μm. h, Quantification of percentage of HFs 
containing at least one Ki67-positive Dct-expressing cell in the upper part of HF. Data 
are presented as mean ± s.d. (n=136, 128, 128 HFs counted from three different mice of 
WT, Tyr::NrasQ61K and Tyr::NrasQ61KSox10LacZ/+ genotype, respectively). j, 
Quantification of percentage of HFs containing at least one Ki67-positive Dct-
expressing cell in the HF bulb. Data are mean ± s.d. (n=212, 227, 251 from three 
different mice of WT, Tyr::NrasQ61K and Tyr::NrasQ61K Sox10LacZ/+ mice respectively). 
P9, postnatal day 9; HF, hair follicle; SG, sebaceous gland.  
 
Figure 4. Sox10 function is crucial for the maintenance of already established 
melanocytic lesions in Tyr::NrasQ61K mice and  is required for proliferation and 
survival of cells with tumorigenic potential in human melanoma cell lines. a, 
Experimental strategy used to analyze the effect of Sox10 haploinsufficiency in 2 
months old Tyr::NrasQ61K mice. b, Pictures of two representative mice 10 months after 
tamoxifen injections show no skin hyperpigmentation in Tyr::NrasQ61KSox10fl/+Tyr-
CreERT2 mice. Scale bars, 5 mm. c, H&E staining and  immunostaining for Dct (green) 
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of skin sections from Tyr::NrasQ61KSox10fl/+ and Tyr::NrasQ61KSox10fl/+Tyr-CreERT2 
mice. Scale bars, 20 μm. d, Quantification of percentage of HF with ectopic Dct-
expressing cells. Data are presented as mean± s.d. (n=394 and 400 HFs counted from 
three mice of each genotype, Tyr::NrasQ61KSox10fl/+ and Tyr::NrasQ61KSox10fl/+Tyr-
CreERT2, respectively). e, Colony formation by human melanoma cells upon lentiviral 
shRNA-mediated knockdown of SOX10 (left, control; right, SOX10 shRNA). Plates 
were stained with crystal violet to visualize colonies. Scale bars, 200 μm. f, Frequency 
of tumor formation in immunodeficient NOD/SCID or Nude mice upon subcutaneous 
injections of melanoma cell lines M010817 and M070302 expressing either SOX10 
shRNA or scrambled control shRNA. g, Heat map of mRNA expression upon SOX10 
KD after 48 and 96 hours in M010817 cell line. The signature used in the heat map was 
compiled from Affymetrix probe sets related to genes involved in apoptosis (61 probe 
sets), cell cycle (127 probe sets), melanocytic differentiation (46 probe sets) and 
mesectodermal differentiation (59 probe sets). h-i, mRNA expression of genes involved 
in apoptosis and cell cycle 96 hours after SOX10 knockdown. n = 3 independent 
experiments. Data are presented as the mean fold change ± s.d. and are normalized to 
the control. HF, hair follicle; SG, sebaceous gland; P0, postnatal day 0; mo, months. 
 
Figure 5. SOX10 is required for proliferation and survival of cells with 
tumorigenic potential in human melanoma cell lines and SOX10 knockdown 
induces fate switch in melanoma cells. a-c, FACS analysis and quantification of 
Annexin V-positive cells upon SOX10 KD after 48 and 96 hours in M010817 cell line. 
For apoptosis analysis, GFP-positive cells were gated (a) and Annexin V-positive cells 
were analyzed after 48 hours (b, left panel) and 96 hours (b, right panel) of SOX10 
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knockdown. c, Quantification of Annexin V-positive cells in GFP-expressing fractions 
in M010817 and A375 cell lines upon SOX10 KD after 48 and 96 hours. Data are 
presented as mean± s.d. n=3 of independent experiments. These data show that SOX10 
knockdown influences survival of melanoma cells. d-f, FACS analysis of cell cycle 
profile in M010817 cell line upon SOX10 knockdown after 96 hours. GFP-positive cells 
were gated (d) and subjected further to PI selection gating. Resulting FACS profiles of 
M010817 control (e, left panel) and M010817 SOX10 shRNA (e, right panel) after 96 
hours of electroporation are presented. f, Quantification of  ratio of cells in G1  phase to 
cells in S plus G2  phases upon SOX10 KD in M010817 and A375 cell lines are 
presented. Data are presented as mean ± s.d. n=3 of independent experiments. These 
data show that SOX10 knockdown results in cell cycle arrest in melanoma cells. g, 
Immunostaining for SOX9 (red) combined with GFP signal (green) showing that 
melanoma cells acquire SOX9 expression upon knockdown of SOX10. h, 
Immunostaining for melanoma markers HMB45/MART-1 (red) combined with GFP 
signal (green) showing the reduction of HMB45/MART-1 expression in SOX10 
knockdown cells. i, Immunostaining for CD271 (p75NTR) (green) and SOX10 (red) 
combined with GFP signal (white) in cells electroporated with SOX10 shRNA 
demonstrating loss of CD271 (p75NTR) positive cells in GFP-expressing cells. j, 
Representative pictures of M010817 cells electroporated with control scr shRNA (j, left 
panel) and SOX10 shRNA (j, right panel) demonstrating the change in morphology and 
smooth muscle-like cell appearance upon SOX10 knockdown. k-l, Quantification of 
HMB45/MART-1-positive cells (k) and CD271 (p75NTR)-positive cells (l) upon SOX10 
KD after 96 hours in M010817 cell line. n = 3 independent experiments. Data are 
represented as mean ± s.d. Cntl, control. Scale bars, 20 μm. 





